Clinical Trials

TxCell undertaking one of largest ever controlled studies for a personalized T cell immunotherapy product . Top line results of this study are expected end 2016/early 2017.TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative,...

Sanofi and Regeneron Pharmaceuticals have reported positive results from the interim analysis of a dose-ranging Phase IIb trial of dupilumab, a fully-human monoclonal antibody, in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is directed against the...

US-based Sarepta Therapeutics has started dosing patients in a clinical trial of its lead exon-skipping therapeutic candidate eteplirsen to treat Duchenne muscular dystrophy (DMD). The open-label trial (Study 204) will be carried out in DMD patients...

TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative,...

Eli Lilly and Company announced the U.S. FDA approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in combination with finasteride significantly improved the...

The news is a remarkable turnaround for the drug, which had looked doomed to failure just a few months ago. In January this year, GlaxoSmithKline returned the rights to the drug following failure in Phase 3 trials. ...

Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel. The company is also conducting ORMD-0801 US...